Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
DANVERS, Mass., May 30, 2017 -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Tuesday, June 6, 2017 at 10:00 a.m. EDT.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
For further information please contact: Ingrid Goldberg Director, Investor Relations 978-646-1590 [email protected]
